Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIPAC-OPC4: Adjuvant PIPAC in Gastric Cancer
NCT04047004Phase 1Completed
- Start
- Mar 2020
- Primary completion
- Jun 2022
- Modality
- DNA Intercalators/Alkylators
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of cisplatin and doxorubicin in gastric adenocarcinoma. Primary endpoints: Medical adverse events at 30 days and Surgical complications at 30 days. Started Mar 2020; status: completed.
02
Drugs
cisplatindoxorubicin
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on NCT04047004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04047004.